Phase 3 Clinical Trials With Primary Completion Dates in January 2016

This is a list of Phase 3 trials with primary completion dates in January 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ADMS Adamas Pharmaceuticals, Inc. 2016-01-01 Phase 3 NCT02274766 Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
CLVS Clovis Oncology, Inc. 2016-01-01 Phase 3 NCT01968213 A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
DERM Dermira, Inc. 2016-01-01 Phase 3 NCT02326272 A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
KERX Keryx Biopharmaceuticals, Inc. 2016-01-01 Phase 3 NCT02268994 KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
MMSI Merit Medical Systems, Inc. 2016-01-01 Phase 3 NCT02159898 EndoMAXX EVT Compared to EndoMAXX
ONTX Onconova Therapeutics, Inc. 2016-01-01 Phase 3 NCT01241500 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts